drugset / Trial / NCT02693080

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

NCT02693080 ↗

Phase 1 Completed 19 enrolled Stanford University
NaSingle-groupOpen-labelDiagnostic

Summary

This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs (metastases) treated with stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that uses an injected dye in order to see how blood flow through tissues, including lung tissue. CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of lung tumors may be predictive of response to treatment and whether lung perfusion characteristics can be used to follow response to treatment.

Timeline

Start
2016-01-19
Primary completion
2020-04-29
Completion
2020-04-29

Drugs

EvaluationDrugModalityDoseRoute
Background Isovue-200 Diagnostic / imaging agent — —